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Introduction
The extracellular matrix and its multiple constituents play both 
a structural and signaling role by interacting with surface recep-
tors that ultimately affect gene expression, cell phenotypes, de-
velopment, and cancer (Ramirez and Rifkin, 2003; Weigelt and 
Bissell, 2008). Decorin, a member of the small leucine-rich 
proteoglycan gene family that harbors one chondroitin/dermatan 
sulfate side chain at its N terminus, was originally named be-
cause of its ability to “decorate” collagen fibrils, thereby regu-
lating fibrillogenesis, a key mechanism of matrix assembly and 
homeostasis (Schaefer and Iozzo, 2008). It was soon discovered 
that decorin regulates the TGF- signaling pathway and also in-
hibits the growth of a variety of tumor cells (Iozzo, 1998) by 
down-regulating the EGF receptor (EGFR; Iozzo et al., 1999b) 
and other members of the ErbB family of receptor tyrosine ki-
nase (RTK; Goldoni and Iozzo, 2008). Decorin suppresses 
tumor cell–mediated angiogenesis by inhibiting the endogenous 
production of vascular endothelial cell growth factor (Grant   
et al., 2002) similar to neutralizing antibodies directed toward 
EGFR (Petit et al., 1997). Genetic deficiency of decorin causes 
intestinal tumor formation through disruption of intestinal cell 
maturation (Bi et al., 2008), whereas mice with a double deficiency 
of decorin and p53 succumb prematurely to aggressive lympho-
mas (Iozzo et al., 1999b). Together, these observations indicate 
that lack of decorin is permissive for in vivo tumorigenesis.
Ectopic expression of decorin induced by stable trans-
genic systems, viral vectors, or inducible promoters attenuates 
the growth of tumor xenografts with diverse histogenetic origin 
(Santra et al., 1995, 2000; Csordás et al., 2000; Reed et al., 
2002, 2005; Tralhão et al., 2003; Biglari et al., 2004; Seidler   
et al., 2006). Decorin slows the growth of squamous cell and 
breast carcinomas by inducing a sustained down-regulation of 
the EGFR (Csordás et al., 2000) and ErbB2 (Santra et al., 2000), 
a process that leads to a p21
WAF1-mediated growth suppression 
and enhanced cytodifferentiation of mammary carcinoma cells 
(Santra et al., 2000). The basic mechanism has been partially 
elucidated and includes direct binding to the EGFR followed by 
protracted internalization of the receptor via caveolar-mediated 
endocytosis (Zhu et al., 2005) and the triggering of apoptosis 
  D
ecorin, a member of the small leucine-rich proteo-
glycan gene family, impedes tumor cell growth   
by down-regulating the epidermal growth factor 
receptor. Decorin has a complex binding repertoire, thus, 
we predicted that decorin would modulate the bioactivity 
of other tyrosine kinase receptors. We discovered that 
decorin binds directly and with high affinity (Kd = 1.5 nM) 
to Met, the receptor for hepatocyte growth factor (HGF). 
Binding of decorin to Met is efficiently displaced by   
HGF and less efficiently by internalin B, a bacterial Met   
ligand. Interaction of decorin with Met induces transient 
receptor activation, recruitment of the E3 ubiquitin ligase 
c-Cbl, and rapid intracellular degradation of Met (half- 
life = 6 min). Decorin suppresses intracellular levels of 
-catenin, a known downstream Met effector, and inhibits 
Met-mediated cell migration and growth. Thus, by antag-
onistically  targeting  multiple  tyrosine  kinase  receptors, 
decorin contributes to reduction in primary tumor growth 
and metastastic spreading.
Decorin is a novel antagonistic ligand of the  
Met receptor
Silvia Goldoni,
1,2 Ashley Humphries,
1,2 Alexander Nyström,
1,2 Sampurna Sattar,
1,2 Rick T. Owens,
3  
David J. McQuillan,
3 Keith Ireton,
4 and Renato V. Iozzo
1,2
1Department of Pathology, Anatomy, and Cell Biology and 
2Cancer Cell Biology and Signaling Program, Kimmel Cancer Center, Thomas Jefferson University,  
Philadelphia, PA 19107
3LifeCell Corporation, Branchburg, NJ 08876
4Department of Molecular Biology and Microbiology, College of Medicine, Burnett College of Biomedical Sciences, University of Central Florida, Orlando, FL 32826
©  2009  Goldoni  et  al.  This  article  is  distributed  under  the  terms  of  an  Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publica-
tion date (see http://www.jcb.org/misc/terms.shtml). After six months it is available under a 
Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, 
as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
T
H
E
J
O
U
R
N
A
L
O
F
C
E
L
L
B
I
O
L
O
G
YJCB • VOLUME 185 • NUMBER 4 • 2009   744
(Fig.  1  C,  bottom).  Interestingly,  decorin  induced  a  marked   
decrease in steady-state levels of Met, as detected by immuno-
blotting (Fig. 1 C, top). It is important to note that Met kinase 
activity was required for decorin-evoked down-regulation of Met, 
as tested by using SU11274, a specific Met tyrosine kinase inhibi-
tor (Berthou et al., 2004; unpublished data). Remarkably, the 
levels of total Met receptor declined very rapidly with a t1/2 of 
6 min (Fig. 1 D) and partially recovered at 60 min after treat-
ment. However, even after 24 h of continuous decorin treatment, 
the Met levels were only 50% of control values (unpublished 
data). The kinetics of decorin-evoked Met phosphorylation were 
similar to those published for HGF in HeLa cells (Hammond   
et al., 2003), with a peak between 5 and 10 min of stimulation.   
In contrast, the kinetics of total Met degradation induced by HGF 
were much slower than those of decorin, showing a comparable 
down-regulation only after a 60-min treatment (Hammond et al., 
2003), although those experiments were performed in full 
serum. These data suggest a role for decorin as a partial agonist 
insofar as it activates the Met kinase domain but with an out-
come different from that evoked by HGF.
Decorin binds directly to the Met receptor: 
functional and biochemical evidence
We  have  previously  shown  that  decorin  binds  directly  to  the 
EGFR,  initiating  a  cohort  of  cellular  responses  (Iozzo  et  al., 
1999b). Receptor cross talk is prevalent in cancer progression, and 
Met and EGFR are no exception, with many studies showing a 
link between the two either through direct interaction or by con-
vergence of downstream signaling (Jo et al., 2000; Birchmeier et al., 
2003; Li et al., 2008a; Reznik et al., 2008). To assess whether the 
observed effects on Met could be indirectly attributed to decorin/
EGFR binding, we used two different EGFR-blocking strate-
gies: either the blocking monoclonal antibody mAb425 (Rodeck 
et al., 1987) or AG1478, a specific EGFR tyrosine kinase inhibitor 
(Levitzki and Gazit, 1995). Preincubation for 1 h with mAb425 
was sufficient to abrogate EGFR activation as demonstrated by a 
complete lack of phosphorylation in response to EGF (Fig. 2 A). 
Blocking EGFR kinase activity with AG1478 gave similar results 
(unpublished data). Even in the absence of EGFR activity, decorin 
evoked a rapid activation of the Met catalytic domain (Fig. 2 B) 
with no change in overall kinetics and a concurrent down-regulation 
of total Met. We conclude that Met receptor activation by decorin 
is independent of the EGFR.
This observation led us to hypothesize that decorin may 
act through a direct interaction with the Met receptor. To ex-
plore  this  possibility,  we  used  a  noncleavable  impermeable 
cross-linker, S-SMPB (sulfo-succinimidyl-4-(p-maleimidophenyl)- 
butyrate). After cross-linking, the Met receptor was immuno-
precipitated with an antibody specific for the intracellular 
C-terminal domain, and immunoblotting was performed to de-
tect Met and decorin. We found that decorin protein core co-
immunoprecipitated with Met in a complex of 190 kD (Fig. 2 C, 
arrows). The size of the complex suggests a 1:1 stoichiometry 
between decorin protein core (50 kD) and the  chain of the 
receptor (140 kD; Fig. 2 C, asterisk).
Next, the physical interaction of decorin with Met was estab-
lished in pull-down experiments using protein A–linked Sepharose 
via caspase-3 activation (Seidler et al., 2006). Moreover, deco-
rin inhibits myeloma cell growth (Li et al., 2008b), and systemic 
delivery of decorin reduces pulmonary metastases in two animal 
models (Goldoni et al., 2008; Shintani et al., 2008). Notably, 
decorin-induced growth inhibition in osteosarcoma MG63 cells 
is overcome by a constitutive activation of EGFR (Zafiropoulos 
et al., 2008).
Because of the complex binding capabilities of decorin   
toward multiple targets (Brandan et al., 2008; Schaefer and Iozzo, 
2008) and its dramatic antioncogenic effects (Reed et al., 2002, 
2005; Goldoni et al., 2008), we predicted a role for decorin in mod-
ulating the bioactivity of other RTK. We discovered that deco-
rin binds directly to the Met receptor, also known as hepatocyte 
growth factor (HGF) receptor, an established mediator of ma-
lignant transformation, invasion, and metastasis (Danilkovitch- 
Miagkova and Zbar, 2002; Birchmeier et al., 2003; Knudsen   
and Vande Woude, 2008). Our findings indicate that decorin is a 
novel antagonistic ligand of the Met receptor. Apart from HGF, 
decorin is the only mammalian ligand known to date. Interaction 
between decorin and the extracellular domain of Met leads to   
receptor down-regulation through a combination of enhanced 
ectodomain shedding and internalization. Decorin-induced inhi-
bition of Met activity results in suppression of key biological 
events. Notably, decorin induces a marked proteasome-dependent 
degradation of the transcription factor -catenin and inhibits 
Met-dependent cell motility. Collectively, our findings point to 
decorin as a novel inhibitor of the Met receptor. The ability of 
decorin to antagonize multiple receptors, including Met, EGFR, 
and ErbB2/ErbB4, suggests that this leucine-rich proteoglycan 
might have therapeutic value in treatment of cancers in which 
several RTKs are coactivated.
Results
Decorin down-regulates the Met receptor
To discover new pathways affected by decorin, we used an anti-
body array system that simultaneously examines the relative Tyr 
phosphorylation level of 42 different RTKs. After a 15-min expo-
sure of quiescent (serum starved) HeLa cells to 100 nM recombi-
nant decorin, there was a rapid phosphorylation of the EGFR 
(Fig. 1 A) in agreement with our previous experiments (Iozzo   
et al., 1999b). In addition, a novel target was found in the Met recep-
tor, which showed a decorin-evoked increase in phosphorylation 
when the cells were quiescent (Fig. 1 A) and a marked suppression 
when the cells were cultured in full serum (Fig. 1 B). Note that 
under the latter conditions, Tyr phosphorylation of EGFR, ErbB2, 
and ErbB4 receptors was markedly down-regulated by decorin in 
full agreement with our previous studies (Santra et al., 2000; Zhu 
et al., 2005), thereby validating our approach.
Next, we performed dose-response and time course experi-
ments to investigate the effects of decorin on Met phosphoryla-
tion kinetics. We used a phosphoantibody specific for the two 
Tyr residues located within the Met catalytic domain, Tyr1234 
and Tyr1235. Decorin treatment of serum-starved cells evoked   
a transient phosphorylation of these residues (Fig. 1 C, top).   
In several experiments, we found a significant peak in phosphory-
lation at 10 min followed by pronounced down-regulation 745 DECORIN AND MET RECEPTOR ACTIVITY • Goldoni et al.
is a protein of similar size to decorin, and is expressed in the same 
eukaryotic cell system (293-EBNA cells).
Two ligands of Met have been previously identified: the 
mammalian HGF and a bacterial leucine-rich repeat surface 
protein called internalin B. HGF plays key roles in promoting 
epithelial cell motility, growth, and differentiation (Birchmeier 
et al., 2003). Internalin B activates Met, leading to internaliza-
tion of the bacterial pathogen Listeria monocytogenes into host 
cells (Shen et al., 2000; Ireton, 2007; Disson et al., 2008). 
Recent structural studies have shown that internalin B binds to the 
first Ig-like domain of Met (Niemann et al., 2007; Niemann et al., 
2008). In contrast, HGF binds with high affinity to the Met ter-
minal Ig3-4 (Basilico et al., 2008) and with lower affinity to the 
semaphorin domain (Stamos et al., 2004). To determine whether 
decorin binds to regions within the Met ectodomain that overlap 
with those used by HGF or internalin B, we performed competi-
tive binding assays. First, we found that internalin B bound with 
high affinity (Kd = 2.16 nM) to Met-Fc (Fig. 3 E). Note that the 
Kd for Met/internalin B was previously reported to be 20–30 nM 
(Machner et al., 2003). A possible explanation for this discrep-
ancy in the observed affinity could be that the Met-Fc used in 
our study is a dimer and fully glycosylated, whereas the Met 
used in the referenced study was a monomer and produced in 
beads, which efficiently bound a Met-Fc chimera comprised of the 
extracellular domain of the Met fused to the Fc region of human 
IgG (Fig. 2 D). By this approach, we were able to efficiently pull 
down both HGF (Fig. 2 E) and decorin protein core (Fig. 2 F). 
Some decorin bound nonspecifically to the beads, but the presence 
of Met-Fc led to a significant enrichment in decorin binding.
Next, we determined the binding affinity of decorin to   
immobilized Met-Fc chimera using solid-phase assays. Both 
decorin and decorin protein core bound to Met-Fc in a satu-
rable manner (Fig. 3, A and B) with Kd of 2.2 nM and 1.5 nM, 
respectively. The biological activity of decorin and decorin pro-
tein core was tested by using fibrillar collagen type I, a known li-
gand for decorin. In this case, decorin and decorin core bound in 
a saturable manner with Kd of 0.25 nM and 0.28 nM, respectively 
(Fig. 3, C and D). In our assay, the binding of HGF alone to Met-
Fc showed a Kd of 0.95 nM ± 0.47 (Fig. S1 A). As a negative con-
trol, we used a mouse monoclonal antibody as immobilized 
substrate, and no significant binding to decorin was observed 
(Fig. S1 B), ruling out the possibility that decorin binds non-
specifically to the Fc portion of the Met-Fc chimera. In addition, 
LG3 (the C-terminal portion of perlecan; Iozzo, 2005) did not   
interact with Met-Fc (Fig. S1 C). This rules out a role for the   
His tag in the binding insofar as LG3 has a His tag as decorin, it 
Figure 1.  Decorin affects Met receptor signal-
ing and turnover. (A) Phospho-RTK arrays. HeLa 
cells were treated with decorin for 15 min. RTK 
membranes were incubated with cell lysates. 
The duplicate dots at each corner represent 
phospho-Tyr positive controls. (B) The same 
experiment as in A using nonquiescent cells. 
(C, top) Representative immunoblot of a short 
decorin time course showing phosphorylation 
of the Met receptor at Tyr1234/5, total Met,   
and -actin. (bottom) Quantification of immuno-
blots similar to those shown in the top from 
three  independent  experiments  performed  in 
triplicate. Values represent the mean ± SEM 
(**, P < 0.01). (D) Best-fit plot of Met receptor 
degradation over time. Relative values were 
obtained  by  scanning  densitometry  (chemi-
luminescence) of blots as in C and represent 
means ± SEM from three independent experi-
ments performed in triplicate.JCB • VOLUME 185 • NUMBER 4 • 2009   746
several other Tyr residues in the cytoplasmic tail of the Met recep-
tor are known to undergo agonist-induced phosphorylation and 
play key roles in downstream signaling (Fig. 4 A; Birchmeier et al., 
2003). For example, phosphorylation of Tyr1349 and Tyr1356 re-
cruit the adaptor proteins Gab1 and Grb2, respectively, which are 
responsible for mediating most of the complex cellular responses 
(motility, growth, and differentiation; Birchmeier et al., 2003). 
Conversely, phosphorylation of Tyr1003 is involved in negative 
regulation of the receptor via recruitment of the E3 ubiquitin ligase 
c-Cbl, which is responsible for Met polyubiquitination and subse-
quent degradation in the proteasome (Petrelli et al., 2002).
Decorin promoted phosphorylation of Tyr1003 (Fig. 4 B, 
top), which was slightly delayed in comparison to HGF, with a 
peak at 15 min (Fig. 4 B, bottom). Like the phosphorylation of resi-
dues 1234/1235 (Fig. 1 C and Fig. 2 B), phosphorylation of 
Tyr1003 in response to decorin was transient, with levels diminish-
ing thereafter (not depicted). In support of this result, c-Cbl was re-
cruited to the Met receptor after decorin treatment (Fig. 4 C).
Interestingly, the C-terminal Tyr1349 failed to be activated 
in response to decorin, whereas cells robustly responded to   
glycosylation-deficient cells. HGF very effectively (50% inhibitory 
concentration [IC50] = 2.3 nM) competed with decorin protein 
core binding to Met-Fc (Fig. 3 F). In comparison, internalin B was 
52-fold less efficient (IC50 = 120 nM) than HGF (Fig. 3 F).   
Because the overall affinity constants for decorin, internalin B, and 
HGF are relatively close (0.95–2.16 nM) in our assays, the conclu-
sions from the competition experiments can be assessed as differ-
ential binding sites on the Met ectodomain for these ligands.
Collectively, our results demonstrate that decorin is a high 
affinity ligand of the Met receptor insofar as it shows saturable ki-
netics of binding and displacement by two established Met ligands. 
Moreover, the more efficient displacement by HGF suggests that 
decorin and HGF bind to overlapping sites on the Met ectodomain 
and further suggests that the decorin’s antagonistic effects might be 
the result of a unique mode of binding within the Met receptor.
Decorin evokes differential tyrosine 
phosphorylation of the Met receptor
In response to decorin binding, the kinase domain of Met is phos-
phorylated (Fig. 1 C and Fig. 2 B). In addition to Tyr1234/5,   
Figure 2.  Decorin interacts with the Met re-
ceptor. (A) 1 µg/ml mAb425, an EGFR-specific 
blocking antibody, was tested before experi-
ments in combination with decorin by evalua-
ting  its  effect  in  inhibiting  EGF-dependent   
(16  nM)  EGFR  phosphorylation.  (B,  top)   
Immunoblot of a short decorin (100 nM) time 
course showing phosphorylation of the Met re-
ceptor at Tyr1234/5, total Met, and -actin in 
the presence or absence of 1 µg/ml mAb425. 
(bottom) Quantification of immunoblots similar 
to those shown in the top panel. Values repre-
sent the mean ± SEM from three independent 
experiments  performed  in  triplicate  (*,  P  < 
0.05; **, P < 0.01). (C) Immunoblots detect-
ing Met (left) and decorin (right) in cells treated 
with decorin protein core for 15 min, cross-
linked  with  500  nM  S-SMPB  for  20  min  at 
37°C, and immunoprecipitated with an anti–C 
terminus Met antibody. Arrows point to a high 
Mr complex of Met and decorin protein core 
(190 kD). The asterisk indicates Met mono-
mer (140 kD). (D) Silver-stained gel. Notice 
that the entire Met-Fc is bound to the protein 
A–Sepharose beads. Smear is the carrier pro-
teins. (E) Immunoblotting (IB) of HGF after pull- 
down with protein A beads–Met-Fc. (F) Immuno-
blotting of decorin after pull-down with either 
protein A beads–Met-Fc or beads alone. Note 
the absence of HGF or decorin in the super-
natants,  indicating  that  essentially  all  of  the 
ligands were bound. IP, immunoprecipitation. 
(D–F) Values shown are given in kiloDaltons.747 DECORIN AND MET RECEPTOR ACTIVITY • Goldoni et al.
also by shedding of its ectodomain (Nath et al., 2001; Athauda 
et al., 2006; Petrelli et al., 2006). Specifically, the shedding is 
induced by a monoclonal Met-blocking antibody (Petrelli et al., 
2006), which is effective in inhibiting primary tumor growth 
and metastastic spreading. Thus, we tested whether decorin 
could use a similar mechanism of action. Media conditioned by 
cells treated with decorin contained higher levels of shed Met 
ectodomain than controls (Fig. S2 A).
It has been reported that the Met ectodomain can be re-
leased  from  the  plasma  membrane  through  activation  of  the 
EGFR, a process that is mediated by a TIMP-3–sensitive pathway 
(Nath et al., 2001). Accordingly, we tested TIMP-2 and TIMP-3 
ability to prevent decorin-dependent Met down-regulation. Both 
matrix metalloproteinase inhibitors were effective in blocking 
decorin activity on the Met receptor (Fig. S2 B, top). We observed 
that the full-length Met levels in cells incubated with the inhibi-
tors were slightly higher than in control cells (Fig. S2 B, bottom). 
This suggests the existence of a basal level of receptor shedding, 
which is inhibited by TIMP-2 and TIMP-3. To test this possibil-
ity, we determined the amount of Met receptor shed into the 
media conditioned by cells treated with decorin in the presence or 
absence of the inhibitors. The results showed that both TIMP-2 
and TIMP-3 reduced the amount of Met shedding (Fig. S2 C). 
Note that the control medium (Fig. S2 C) was conditioned for   
24 h, showing a significant level of basal Met shedding (compare 
with Fig. S2 A).
To  verify  the  contribution  of  Met  internalization  to  Met 
down-regulation upon decorin binding, HeLa cells were treated for 
HGF (Fig. 4 D). This finding was unexpected, given that decorin 
induces efficient activation of Met, as assessed by phosphoryla-
tion of the catalytic Tyr1234/5 (Fig. 1 C and Fig. 2 B). Moreover, 
decorin induced robust recruitment of Grb2 to the Met receptor 
(Fig. 4 E). Because phosphorylated Tyr1356 serves as docking 
site for Grb2, this finding strongly suggests that decorin induces 
efficient phosphorylation of this Tyr residue. Notably, Tyr1356 
is essential for receptor internalization, and Grb2 also indirectly 
recruits c-Cbl, leading to Met degradation (Li et al., 2007). Un-
fortunately, we were unable to directly assess phosphorylation 
of Tyr1356 because of the fact that phospho-specific antibodies 
recognizing this residue are not commercially available.
Collectively, our results show that decorin differentially   
affects key Tyr residues involved in Met signaling and homeo-
stasis, inducing efficient phosphorylation of Tyr1356 and Tyr1003 
while inhibiting phosphorylation of Tyr1349, the sole Tyr associ-
ated with downstream signaling events. Decorin and HGF acti-
vate the receptor in subtly different ways, perhaps by inducing 
different receptor conformations. This ability may be responsible 
for the more efficient down-regulation of Met caused by decorin 
(Fig. 4, B and D, top) and the lack of downstream signaling   
(Fig. 4 D, bottom).
Decorin causes Met down-regulation  
by inducing both ectodomain shedding  
and internalization
It is known that Met can be down-regulated not only via Cbl-
mediated ubiquitination and degradation in the proteasome, but 
Figure 3.  Affinity interaction between decorin and the Met receptor. (A–E) Ligand-binding assays using decorin, decorin protein core, or internalin B   
as soluble ligands and Met-Fc or fibrillar collagen I as immobilized substrates. (F) Competition experiments using constant amounts of decorin core (10 nM) 
and increasing amounts of internalin B or HGF as indicated. Notice that only at high molar ratios (20:1 and 40:1), internalin B significantly (70%) 
reduces decorin protein core binding to the Met (IC50 = 180 nM). In contrast, HGF is much more efficient (IC50 = 2.5 nM) in displacing decorin core. 
Values represent the mean ± SEM.JCB • VOLUME 185 • NUMBER 4 • 2009   748
absence of decorin. AG1478 was not capable of inhibiting decorin 
effect on -catenin levels, whereas SU11274 blocked decorin-
evoked -catenin degradation (Fig. 5 C). Importantly, the effect of 
decorin on the -catenin pathway was direct and not the result of 
induction of apoptosis as proven by lack of poly ADP-ribose poly-
merase (PARP) cleavage after 6-h treatment (Fig. 5 C, top). In 
agreement with the biochemical data, the total levels of -catenin 
were markedly reduced by decorin treatment as detected by qualita-
tive and quantitative fluorescence microscopy (Fig. 6, A, C, and E). 
Notably, there was a marked displacement of -catenin from peri-
nuclear to plasmalemmal regions (Fig. 6, B and D). Finally, we 
tested whether decorin could cause -catenin degradation in the 
presence or absence of LiCl, a known inhibitor of GSK3 (Klein 
and Melton, 1996). The results clearly showed that LiCl potently 
stabilized -catenin levels in the absence of decorin but was not 
capable of inhibiting decorin-evoked -catenin down-regulation 
(Fig. 6 F). These findings were corroborated by functional tests 
assessing  -catenin  transcriptional  activity.  We  performed 
transient cell transfection assays using the TopFlash reporter vec-
tor, which drives the expression of a luciferase reporter gene under 
the control of a T cell factor promoter, which is activated by endog-
enous -catenin. Decorin significantly inhibited -catenin activity 
in the presence or absence of LiCl (Fig. 6 G). The persistence of 
decorin activity in the presence of LiCl suggests that decorin 
evokes down-regulation of -catenin independently of the canoni-
cal Wnt pathway, which requires GSK3.
5 and 30 min, subjected to immunostaining with a Met N terminus 
antibody, and analyzed by fluorescence microscopy (Fig. S2 D). 
Over time, decorin induced receptor relocation from the plasma 
membrane to intracellular compartments and perinuclear regions. 
This evidence was corroborated by biochemical data showing the 
presence of Met upon decorin treatment followed by trypsin diges-
tion (Fig. S2 E). This assay is based on the fact that only internal-
ized Met is not accessible to digestion. Collectively, our results 
provide a novel mechanism of action for decorin: inhibition of the 
Met receptor biological activity via a dual activity comprising en-
hanced shedding and intracellular degradation.
Decorin down-regulates -catenin and 
induces apoptosis via the Met receptor
Next, we investigated whether decorin-evoked Met down- 
regulation could impair the -catenin pathway, a known down-
stream effector of Met (Monga et al., 2002; Herynk et al., 
2003; Rasola et al., 2007). After decorin treatment, -catenin 
levels declined by 70% and 90% after 6 h and 24 h, respec-
tively (Fig. 5 A). This degradation occurred via the proteasome, 
the main degradation pathway for -catenin (Aberle et al., 1997), 
insofar as it was completely blocked by the proteasome inhibitor 
lactacystin (Fig. 5 B).
Next, we preincubated the cells with AG1478 and SU11274, 
EGFR and Met-specific tyrosine kinase inhibitors (Levitzki and 
Gazit, 1995; Berthou et al., 2004), respectively, in the presence or 
Figure 4.  Decorin induces differential and selective phos-
phorylation of Met Tyr residues. (A) Diagram of the main Met 
receptor Tyr phosphorylation sites and adaptor proteins. CAS, 
Crk-associated substrate; P, phosphate. (B, top) Representa-
tive immunoblots of a short decorin (100 nM) time course 
showing phosphorylation of the Met receptor at Tyr1003 and 
total Met amount vis à vis 1.5 nM HGF. (bottom) Quantifi-
cation of immunoblots from three independent experiments.   
(C) Coimmunoprecipitation of c-Cbl and Met using an anti-
body directed toward the intracellular domain of Met. 100 nM   
decorin treatment was performed for 10 min. (D, top) Rep-
resentative immunoblot showing phosphorylation of the Met 
receptor at Tyr1349 and total Met after 100 nM decorin 
treatment vis à vis 1.5 nM HGF. (bottom) Quantification of 
immunoblots from three independent experiments performed 
in triplicate. (E) Recruitment of Grb2 to the Met receptor medi-
ated by 100 nM decorin. Coimmunoprecipitation of the Met 
receptor and Grb2 using an anti-Met C terminus antibody for 
the immunoprecipitation (IP) and either the same antibody 
or an anti-Grb2 monoclonal antibody for the immunoblotting 
(IB). Values represent the mean ± SEM (*, P < 0.05; **, P <   
0.01;  ***,  P  <  0.001).  All  of  the  relative  values  were   
obtained by scanning densitometry (chemiluminescence). 
(B–E) Values shown are given in kiloDaltons.749 DECORIN AND MET RECEPTOR ACTIVITY • Goldoni et al.
in the presence or absence of AG1478, H9786, a Met-blocking 
antibody, or the combination of both. Decorin significantly in-
hibited cell migration compared with control cells (Fig. S4). 
Both AG1478 and H9786, used alone, were effective but to a 
lesser extent than decorin. Interestingly, when decorin was used 
in combination with either inhibitor, it prevented wound closure 
even further than the individual compounds. When decorin was 
added in the presence of both inhibitors, it did not have any   
additional effect (Fig. S4, bottom). These data support the idea 
that both Met and EGFR are important to sustain cell migration 
and that decorin inhibits in vitro cell motility by a dual action on 
both receptors. Note that decorin is capable of down-regulating 
the Met receptor also in full-serum medium (Fig. S3 C), sup-
porting the biological data regarding inhibition of the -catenin 
pathway and cell migration, both performed in the presence of 
serum. In addition, once decorin is removed from the cells, Met 
expression is recovered over time, indicating that the cells are 
healthy and apoptosis is not occurring.
Discussion
The multifaceted ability of decorin to retard in vivo tumor growth 
and metastatic spreading has a mechanistic explanation in deco-
rin’s ability to down-regulate multiple signaling pathways. We 
show for the first time that decorin is a novel endogenous antago-
nistic ligand of the Met receptor. Signaling mediated by HGF/Met 
axis promotes multiple biological activities, including survival, 
Next, on the basis of our previous studies showing that 
decorin induces apoptosis of A431 (Seidler et al., 2006) and 
MTLn3 (Goldoni et al., 2008) cells, we tested whether the same 
would  happen  in  HeLa  cells  and  whether  the  Met  receptor 
could be linked to decorin-evoked apoptosis. Decorin treatment 
stimulated significant PARP cleavage after 24 h, and this effect 
was blocked by SU11274 (Fig. S3 A). Moreover, decorin in-
duced caspase-3/7 activity comparable with the levels induced 
by etoposide, an inhibitor of the topoisomerase II enzyme, and 
it did so in a Met-dependent manner (Fig. S3 B). VAD, a pan-
caspase inhibitor, was used to block decorin’s activity, and its 
effects can be compared to those evoked by the Met kinase in-
hibitor SU11274. These results suggest that Met phosphoryla-
tion is required for decorin-evoked apoptosis and reinforce our 
evidence that the Met receptor is a key player in decorin’s 
mechanism of action.
Decorin inhibits cell motility by a 
mechanism that involves both Met  
and EGFR
Deregulation of the Met receptor has been linked to the invasive 
behavior of tumor cells (Birchmeier et al., 2003). We have re-
cently shown that decorin can prevent metastastic spreading to 
the lungs in a breast cancer model (Goldoni et al., 2008). In this 
study, we add an in vitro functional assay to support the rele-
vance of our findings. HeLa cells were grown to confluency, 
“scratched” to allow motility, and treated with decorin for 24 h 
Figure 5.  Decorin down-regulates -catenin via the Met receptor. (A, top) Representative immunoblots of HeLa cells treated with 100 nM decorin for the 
times indicated and probed for -catenin. Tubulin was used as a loading control. (bottom) Quantification of immunoblots as those presented in the top panel 
from three independent experiments. (B, top) -Catenin levels after treatment with 100 nM decorin for 30 min in the presence or absence of 10 µM of the 
proteasome inhibitor lactacystin. Cells were preincubated with lactacystin for 1 h before adding decorin. (bottom) Quantification of immunoblots as those 
presented in the top panel from three independent experiments. (C, top) -Catenin and PARP immunoblots after treatment with 100 nM decorin for 6 h in 
the presence or absence of the tyrosine kinase inhibitors AG1478 and SU11274 (both 1 µM) as indicated. Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was used as loading control. (bottom) Quantification of immunoblots as those presented in the top panel from three independent experiments 
performed in triplicate. Values represent the mean ± SEM (*, P < 0.05; **, P < 0.01). All of the relative values were obtained by scanning densitometry 
(chemiluminescence). Values shown in blots are given in kiloDaltons.JCB • VOLUME 185 • NUMBER 4 • 2009   750
repeats with homology to decorin, mimics HGF-induced receptor 
trafficking (Li et al., 2005) and causes sustained activation of the 
Met receptor (Shen et al., 2000), leading to bacterial internalization 
into host cells (Shen et al., 2000; Ireton, 2007; Disson et al., 2008). 
The 213–amino acid leucine-rich repeat portion of internalin B is 
sufficient for entry into mammalian cells (Braun et al., 1999). The 
recent cocrystallization of internalin B with the ectodomain of the 
Met receptor has shown that internalin B complexes with the first 
Ig domain of the receptor (Niemann et al., 2007; Niemann et al., 
2008). This interaction keeps Met in an active configuration while 
maintaining the flexibility in the Met semaphorin domain, where 
HGF binds with low affinity (Stamos et al., 2004). The interaction 
interface includes the concave part of the leucine-rich domain of 
internalin B and a loop that protrudes from the first Ig-like domain 
of the Met receptor (Niemann et al., 2008). Notably, several key 
aromatic amino acids within the concave face of internalin B are 
proliferation, motility/invasion, and angiogenesis (Trusolino and 
Comoglio, 2002; Birchmeier et al., 2003). Deregulation of the Met 
signaling pathway leads to uncontrolled growth and transforma-
tion, as shown by the TPR-Met, an oncogene that exhibits constitu-
tive tyrosine kinase activation, and by activating mutations of Met 
intracellular domain in both hereditary and sporadic cancers   
(Gentile et al., 2008). Our results indicate that decorin is an inhibi-
tor of multiple RTKs, insofar as it down-regulates the Met receptor 
as well as ErbB family members. The unique activity of decorin as 
a Met antagonist is manifested by a rapid induction of both Met re-
ceptor shedding and internalization with consequent downstream 
degradation of -catenin, which is required for cell survival.
To date, there is only one known mammalian ligand of the 
Met receptor (i.e., HGF) and one bacterial protein, internalin B, 
which is synthesized and partly secreted by Lysteria monocyto-
genes. Internalin B, a protein containing seven leucine-rich tandem 
Figure 6.  Decorin attenuates -catenin levels and transcriptional activity. (A–D) Representative -catenin immunofluorescence images of HeLa cells after 
a 2-h incubation with or without 100 nM decorin. Notice the marked decline in -catenin levels throughout the cytoplasm and perinuclear regions in the 
decorin-treated cells. In contrast, the plasma membrane localization of -catenin increases (D, arrows). Nu, nucleus. Bars: (A and C) 50 µm; (B and D) 10 µm. 
(E) Quantification of the fluorescence intensity of images similar to those shown in A and C. The values represent the mean ± SEM of 12 images (120 
cells/image) from four independent experiments. (F) Decorin inhibits -catenin activity via a GSK3-–independent mechanism. Representative -catenin   
immunoblot of HeLa lysates treated with 100 nM decorin for 6 h in the presence or absence of 30 mM of the GSK3- inhibitor LiCl. Cells were preincubated 
with LiCl for 1 h in full serum before decorin treatment. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control. (G) HeLa 
cells were cotransfected with the TopFlash vector and a vector carrying the R. reniformis luciferase. 12 h after transfection, cells were treated with or without 
100 nM decorin or LiCl for 6 h. Luciferase activity was measured after incubation with the cognate substrate luciferin. The values were normalized on   
R. reniformis luciferase activity. Cells preincubated with 30 mM LiCl, as in F, showed the same degree of reduction in luciferase activity when treated with 
decorin. Notice that LiCl enhances -catenin activity (***, P < 0.001). The values represent the mean ± SEM of five independent experiments performed 
in triplicate. TCF, T cell factor.751 DECORIN AND MET RECEPTOR ACTIVITY • Goldoni et al.
for tumorigenesis, as we hypothesized previously (Iozzo et al., 
1999a), thereby providing in vivo evidence that -catenin might 
be regulated by extracellular signaling events evoked by decorin.
How does decorin induce protracted Met degradation? In 
the case of the EGFR, EGF but not TGF- induces efficient recep-
tor internalization and degradation. EGF remains closely linked   
to its receptor during clathrin-dependent endocytosis, whereas 
TGF- rapidly dissociates from the receptor in the acidic micro-
environment of early endosomes, resulting in receptor recycling 
(Schlessinger, 2000). Decorin causes a caveolar-mediated endo-
cytosis of the EGFR, and even after 30 min, decorin and EGFR 
colocalize within late endocytic compartments and subsequently 
within lysosomes (Zhu et al., 2005). This mechanism might ex-
plain the lower levels of EGFR after decorin treatment due in part 
to a reduced receptor recycling to the surface. A similar scenario 
could occur with the Met receptor, although we have not formally 
shown that Met internalization and degradation occur via a   
caveolar-mediated endocytosis. This idea is supported by a recent 
study, which has shown that both internalin B and the leucine-rich 
repeats of internalin B, the region that shares analogy with decorin, 
are properly internalized and remain associated with Met during 
transit through early and late endosomes when provided as soluble 
ligands to HeLa cells (Gao et al., 2009). Thus, one possibility is 
that HGF/internalin B, as agonistic ligands for Met, are internal-
ized via a clathrin-mediated pathway and in analogy with EGF/
EGFR, clathrin-mediated internalization has been shown to be es-
sential for sustained receptor signaling (Sigismund et al., 2008). 
In contrast, antagonistic ligands such as decorin could induce in-
ternalization via a caveolar-mediated pathway, leading to attenu-
ated signaling and intracellular proteolysis of the receptor.
The ability of decorin to differentially phosphorylate Met 
receptor Tyr residues is fascinating. More investigation into this 
novel decorin mechanism of action will be needed in the future, 
and most likely, more information regarding the peculiar Met 
conformation induced by decorin binding will shed light onto the 
phosphorylation events described in this study. Notably, coactiva-
tion of RTKs affects the response of tumor cells to targeted thera-
pies (Stommel et al., 2007), and amplification of the Met-encoding 
gene promotes drug resistance in ErbB-driven cancers (Engelman 
et al., 2007). Although in the past main efforts were aimed at de-
veloping highly specific inhibitors acting on single RTKs, more 
recently there has been a general consensus that molecules inter-
fering simultaneously with multiple RTKs might be more effec-
tive than single target agents (Knudsen and Vande Woude, 2008). 
In this perspective, the activity of decorin, and perhaps of other 
molecules harboring leucine-rich repeats, might represent a novel 
therapeutic modality against metastatic cancer.
Materials and methods
Cell culture and materials
HeLa cells were obtained from American Type Culture Collection and main-
tained in DME (Mediatech) supplemented with 10% FBS (PAA Laboratories, 
Inc). Dulbecco’s phosphate buffer saline was purchased from Mediatech. 
Cell culture supplies were purchased from Thermo Fisher Scientific. The fol-
lowing antibodies were used: monoclonal mouse anti-Grb2, anti–-catenin, 
antiphosphotyrosine  HRP  conjugated  (BD),  anti–-actin  (Sigma-Aldrich), 
anti-PARP (BD), monoclonal rabbit against EGFR-Tyr
1173, Met-Tyr
1234/5, Met-
Tyr
1003, Met-Tyr
1349 (Cell Signaling Technology), polyclonal against Met   
required for Met binding and internalization of the bacteria 
(Machner et al., 2003). These results have been confirmed in the 
aforementioned cocrystallization study (Niemann et al., 2007). 
Mutation of each of these residues (Fig. S5 A) abolishes binding 
to the Met receptor (Machner et al., 2003). Very importantly, a 
specific sequence of internalin B, encoding Y170 (required for 
Met binding) and surrounding residues, is highly analogous to a 
sequence of mammalian decorin (Fig. S5 B). This highly con-
served motif suggests that both proteins have evolved to fulfill a 
common function, i.e., interacting with the Met receptor, albeit 
with divergent outcomes.
In contrast to internalin B, HGF binds with low affinity to 
the Met semaphorin domain (Stamos et al., 2004) and with high 
affinity to the terminal Ig3-4 (Basilico et al., 2008). This is in 
agreement with early biochemical experiments demonstrating 
that internalin B and HGF do not substantially compete for re-
ceptor occupancy (Shen et al., 2000). We discovered that decorin 
is readily displaced by HGF (IC50 = 2.3 nM) from binding to 
the immobilized Met ectodomain fused to the dimerizing Fc 
fragment. In contrast, internalin B was much less efficient in dis-
placing decorin binding to Met-Fc because it required >50-fold 
higher concentrations (IC50 = 120 nM). These findings suggest 
that decorin binds to a similar location of the Met ectodomain 
where HGF binds with additional secondary sites overlapping 
with internalin B binding.
In spite of the fact that decorin mode of binding to the Met 
ectodomain is apparently similar to that of HGF, decorin evokes a 
profound antagonistic effect on the receptor signaling by inducing 
both physical and functional receptor down-regulation and by 
triggering apoptosis via induction of caspase-3/7 activity. More-
over, decorin causes Met-mediated down-regulation of -catenin 
levels and transcriptional activity. It is well established that the 
Met receptor not only physically interacts with -catenin on the 
cell surface but upon HGF binding, also phosphorylates -catenin 
and triggers its translocation into the nucleus and consequent 
transcription of genes vital for cell proliferation and migration 
(Monga et al., 2002; Müller et al., 2002; Herynk et al., 2003; 
Ishibe et al., 2006; Rasola et al., 2007). Importantly, the Met re-
ceptor and -catenin are engaged in a positive feedback loop that 
sustains tumor growth and invasion, where -catenin drives Met 
receptor expression (Rasola et al., 2007). -Catenin is a key player 
in Wnt signaling and plays a central role in cancer development 
(Clevers, 2006). For instance, -catenin regulates both differenti-
ation and proliferation of intestinal epithelial cells by enhancing 
the expression of genes, such as cyclin D1 and D4, associated 
with tumor progression. The ability of exogenous decorin to sup-
press -catenin levels and transcriptional activity, coupled with 
the decorin-evoked translocation of -catenin from the peri-
nuclear to plasmalemmal compartments, suggests that decorin 
signaling affects the -catenin pathway. Our data show that this 
effect is mediated through the Met pathway. A recent study using 
decorin-deficient mice has shown that 30% of these mutant 
mice develop intestinal tumors, a process that is accelerated and 
amplified when the decorin-deficient animals are subjected to a 
high risk diet (Bi et al., 2008). Notably, the endogenous -catenin 
levels were markedly increased in the intestinal epithelium of the 
decorin-null mice, suggesting that lack of decorin is permissive JCB • VOLUME 185 • NUMBER 4 • 2009   752
increasing amounts of each ligand and extrapolating from the generated 
standard curves.
Ectodomain shedding and slot blot
HeLa cells were serum starved overnight and treated with 100 nM decorin 
for 5–30 min. Conditioned media from decorin-treated cells and controls 
were collected, slot blotted, and probed for the N-terminal domain of the 
Met receptor. For the inhibition of shedding experiments, 1 µM TIMP-2 and 
TIMP-3 were incubated for 30 min before decorin treatment (100 nM for 
30 min). Both lysates and media were collected and analyzed by Western 
analysis and slot blot, respectively. Lysates were probed with a Met anti-
body recognizing the intracellular domain of the receptor, whereas media 
with an antibody raised against the Met extracellular domain.
Met internalization experiments
Cells for immunofluorescence were grown on chamber glass slides, treated 
with decorin, washed with PBS, fixed in ice-cold methanol for 5 min, and 
stained according to standard procedures. To detect Met, the AF276 anti-
body (R&D Systems) raised against the N terminus domain of the receptor 
was  used  followed  by  an  FITC-conjugated  donkey  anti–goat  antibody 
(Santa Cruz Biotechnology, Inc.). Images were acquired on a laser-scan-
ning confocal microscopy system (LSM 510 META; Carl Zeiss Inc.) driven 
by imaging software (LSM 510; Carl Zeiss, Inc.). 63× magnification was 
used with a 1.25 objective lens aperture. Confocal image processing, in-
cluding z stacks, was performed with ImageJ (National Institutes of Health). 
Contrast enhancement was applied uniformly to all panels. A microscope 
(BX51; Olympus) driven by SPOT Advanced imaging software (version 
4.0.9; Diagnostic Instruments, Inc.) was used to acquire fluorescence   
images with 40× magnification and 0.75 aperture. FITC signal was acquired 
at 25°C. Vectashield mounting medium was purchased from Vector Labo-
ratories. Approximately 8 × 10
6 HeLa cells were serum starved for 1 h be-
fore decorin treatment (100 nM for 5 and 30 min). Cells were trypsinized 
with 0.2% trypsin (Cellgro) for 5 min at 37°C and pelleted by centrifuga-
tion at 300 g for 5 min. The pellet was dissolved in RIPA buffer, and sam-
ples were run on SDS-PAGE.
-Catenin experiments and migration assays
For the -catenin experiments, subconfluent HeLa cells in DME full serum 
were used. Cells were treated with 100 nM decorin from 30 min to 24 h. 
For the GSK3- inhibition experiments, cells were incubated with 30 mM 
LiCl for 1 h before decorin treatment. Cells for immunofluorescence were 
grown on chamber slides, treated with decorin, fixed in ice-cold methanol for 
5 min, and stained according to standard procedures. To detect the -catenin 
signal, a rhodamine-conjugated goat anti–mouse antibody was used (Santa 
Cruz Biotechnology, Inc.). To study the effect of decorin on -catenin tran-
scriptional activity, we used the TopFlash luciferase reporter vector (Add-
gene).  TopFlash  vector  was  provided  by  M.  Pacifici  (Thomas  Jefferson 
University, Philadelphia, PA). Subconfluent HeLa cells in 12-well plates were 
transfected overnight with TopFlash and a Renilla reniformis luciferase re-
porter vector (phRL-TK; Promega) as transfection control in the ratio 10:1 
(TopFlash:R. reniformis) using Lipofectamine2000 (Invitrogen). The next day, 
media were changed and cells were treated with or without 30 mM LiCl for 
1 h before decorin (100 nM) stimulation for 6 h. Cells were lysed, and the 
luciferase activity was measured using a dual luciferase assay kit (Promega). 
The FopFlash mutant was used vis à vis the TopFlash vector as negative con-
trol to evaluate the background signal. No luciferase activity was observed 
with the FopFlash vector.
For migration assays, HeLa cells were grown to confluency in 12-well 
plates and scratched with a pipette tip. Cells were incubated for 24 h with 
or without 100 nM decorin, 1 µM AG1478, and 2 µg/ml Met-blocking anti-
body H9786 in full serum. Blocking agents were incubated for 1 h before 
decorin treatment. An inverted phase-contrast microscope (IM; Olympus) 
with 10× magnification and 0.25 aperture was used. Pictures were taken 
over time with a digital microscope camera (DP12; Olympus).
Quantification and statistical analysis
Immunoblots were quantified by scanning densitometry using Scion Image 
software (National Institutes of Health). Graphs were generated using Sigma-
Stat (version 3.10; Systat Software, Inc.). Significance of the differences was 
evaluated by Student’s t test. Fluorescence intensity was quantified by measur-
ing pixels with ImageJ software. In the scratch assay, wound closure was mea-
sured with ImageJ. The mean of three linear distances between the two edges 
of the wound was measured. Three wounds per condition were analyzed. 
Three independent experiments were run. All data presented were collected 
from three independent experiments run in triplicates or quadruplicates.
C terminus (Santa Cruz Biotechnology, Inc.), Met N terminus (H9786 [Sigma-
Aldrich] and AF276 [R&D Systems]), and HGF (Abcam). Lactacystin was 
purchased from Sigma-Aldrich. Anti–human decorin antibody (LC-001b) 
was provided by LifeCell Corporation. EGFR-blocking antibody mAb425 
was provided by U. Rodeck (Thomas Jefferson University, Philadelphia, PA). 
The EGFR tyrosine kinase inhibitor, AG1478, was obtained from EMD. 
HRP-conjugated donkey anti–rabbit and sheep anti–mouse were purchased 
from Jackson ImmunoResearch Laboratories. Protein G– and A–Sepharose 
beads were obtained from GE Healthcare. S-SMPB and SuperSignal West 
Pico chemiluminescence substrate were purchased from Thermo Fisher Sci-
entific. HGF, TIMP-2, and TIMP-3 were purchased from R&D Systems. Rat 
tail collagen type I was obtained from BD. Human recombinant decorin 
was expressed and purified as described previously (Zhu et al., 2005). 
Decorin harbors one glycosaminoglycan side chain and is fully glycosyl-
ated. Decorin protein core was obtained by expressing a mutant at the   
glycosaminoglycan chain attachment site. Decorin protein core is expressed 
in a mammalian cell system and is fully glycosylated.
Phospho-RTK arrays, time course experiments, and blocking experiments
Arrays were purchased from R&D Systems. Array membranes were incu-
bated with cell lysates and processed as recommended by the manufactur-
er’s protocol using a Phospho-Tyr–specific antibody. Approximately 8 × 10
6 
HeLa cells were either serum starved or maintained in full serum overnight 
and treated with 100 nM decorin for 15 min or left untreated. After decorin 
incubation, cells were washed with ice-cold PBS and lysed with a buffer 
containing 1% NP-40, 20 mM Tris-HCl, pH 8.0, 137 mM NaCl, 10% glyc-
erol, 2 mM EDTA, 1 mM Na3VO4, 10 µg/ml aprotinin, and 10 µg/ml leu-
peptin for 30 min. Protein assay (Bio-Rad Laboratories) was performed 
before incubating the lysates with the RTK membranes. HeLa cells were 
serum starved overnight before treatment with 100 nM decorin for 5, 10, 
15, 30, and 60 min. Cells were washed with ice-cold PBS and lysed in RIPA 
buffer. 10 µg/ml EGFR-blocking antibody mAb425 or 1 µM AG1478 were 
incubated with or without decorin. HGF was used at 1.5 nM. Lysates were 
resolved on an 8% SDS-PAGE. Cells were preincubated with mAb425 or 
AG1478  for  1  h  before  decorin  treatment.  Efficiency  of  mAb425  and 
AG1478 was measured by testing their ability to block EGFR phosphoryla-
tion evoked by EGF (16 nM for 5 min).
Cross-linking and immunoprecipitation
Cells were treated with or without 220 nM decorin protein core for 15 min 
and incubated with 0.5 mM of the noncleavable cross-linker S-SMPB for   
20 min at 37°C (Zhu et al., 2005). At the end, reactions were quenched 
with a 90-mM glycine solution. Cells were washed with ice-cold PBS and 
lysed with an NP-40–containing buffer (as described in Phospho-RTK ar-
rays, time course…). Cell extracts were subjected to immunoprecipitation 
with an anti–C terminus Met receptor antibody, separated on a 6% SDS-
PAGE, and immunoblottings for Met and decorin were performed. Met 
was also immunoprecipitated to examine c-Cbl and Grb2 recruitment to 
the receptor before and after decorin treatment. Approximately 3 × 10
6 
HeLa cells were serum starved overnight for this purpose.
Pull-down– and solid-phase–binding assays
Human Met-Fc chimera (Sigma-Aldrich) was bound to protein A–Sepharose 
beads (GE Healthcare). 2 µg human Met/Fc chimera was added to 20 µl 
protein A–Sepharose beads. After an overnight incubation with rotation at 
4°C, the beads were extensively washed with PBS and resuspended in 400 µl 
of serum-free medium containing Complete Mini protease inhibitor (Roche). 
The mixture was incubated with equimolar amounts of various ligands at 
37°C for 3 h. The beads were collected by centrifugation, extensively washed 
with a buffer containing 0.1% Triton X-100, boiled in reducing sample buffer, 
and subjected to electrophoresis on an 8% SDS-PAGE. In these experiments, 
antibodies against human HGF (Abcam) and decorin (Santa Cruz Biotech-
nology, Inc.) were used. ELISAs were performed following a standard proto-
col.  The  substrates,  either  Met-Fc  (100  ng/well)  or  neutralized  fibrillar 
collagen type I (1 mg/ml; 50 µl/well), were allowed to adhere to the wells 
(BD) overnight at room temperature in the presence of carbonate buffer, pH 
9.6. Plates were washed with PBS and incubated for 3 h with serial dilutions 
of decorin or decorin core. In the competition experiments, decorin core was 
kept at constant concentration (10 nM) and incubated with increasing con-
centrations of either internalin B or HGF. After ligand incubation, plates were 
extensively washed with PBS, blocked with 1% BSA solution in PBS, and in-
cubated with primary and HRP-conjugated secondary antibodies. Signal 
was developed using Sigma-Fast tablets (Sigma-Aldrich) and read at 450-nm 
OD. To correct for antibody affinity, the values obtained were converted to 
bound ligand (nanomolars) by performing separate ELISA experiments using 753 DECORIN AND MET RECEPTOR ACTIVITY • Goldoni et al.
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